Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Sanofi to acquire biotech firm Synthorx for USD 2.5 billion

      Sanofi to acquire biotech firm Synthorx for USD 2.5 billion

      Medical Dialogues Bureau10 Dec 2019 11:15 AM IST
      "This acquisition ... is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations,"...
      JnJ CEO declines to appear at US congressional hearing on carcinogen in baby powder

      JnJ CEO declines to appear at US congressional hearing on carcinogen in baby powder

      Medical Dialogues Bureau10 Dec 2019 9:15 AM IST
      JnJ spokesman Ernie Knewitz said that the subcommittee had rejected the company's offers to send a talc testing expert or a JnJ executive in charge of...
      Grifols Alzheimers trial shows positive results

      Grifols Alzheimers trial shows positive results

      Medical Dialogues Bureau10 Dec 2019 9:00 AM IST
      The latest results strengthen Grifols' research on plasma protein replacement therapies, the company said.New Delhi: Spain's Grifols said on Friday...
      Amgen biosimilar to JnJ arthritis drug Remicade gets USFDA approval

      Amgen biosimilar to JnJ arthritis drug Remicade gets USFDA approval

      Medical Dialogues Bureau9 Dec 2019 1:00 PM IST
      Amgen Inc's biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune...
      Bristol-Myers, bluebird cancer therapy meets goal in mid-stage trial

      Bristol-Myers, bluebird cancer therapy meets goal in mid-stage trial

      Medical Dialogues Bureau9 Dec 2019 9:15 AM IST
      The study evaluated the efficacy and safety of the therapy, Ide-cel, in patients who had received three prior treatments for multiple myeloma, a...
      Bayer, plaintiffs to postpone more glyphosate lawsuits for settlement talks

      Bayer, plaintiffs to postpone more glyphosate lawsuits for settlement talks

      Medical Dialogues Bureau9 Dec 2019 9:00 AM IST
      Bayer acquired the weed killer brands last year as part of a $63 billion takeover of Monsanto, has ruled out pulling the products from the U.S....
      Generic versions of Novartis blockbuster MS drug Gilenya gets USFDA green flag

      Generic versions of Novartis blockbuster MS drug Gilenya gets USFDA green flag

      Medical Dialogues Bureau8 Dec 2019 9:38 AM IST
      The approval allows HEC Pharm Co Ltd, Biocon Ltd and Sun Pharmaceutical Industries Ltd to produce Gilenya for the treatment of relapsing forms of MS...
      AstraZeneca-Merck cancer drug Lynparza wins approval in China

      AstraZeneca-Merck cancer drug Lynparza wins approval in China

      Medical Dialogues Bureau8 Dec 2019 9:20 AM IST
      Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, AstraZeneca and Merck...
      GSK seeks USFDA approval for investigational HIV treatment Fostemsavir

      GSK seeks USFDA approval for investigational HIV treatment Fostemsavir

      Medical Dialogues Bureau8 Dec 2019 9:15 AM IST
      GSK Plc's Fostemsavir is being developed for use in combination with other antiretroviral agents in adults who have been previously taken treatments...
      Enzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concerns

      Enzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concerns

      Medical Dialogues Bureau8 Dec 2019 9:02 AM IST
      Enzyvant was hoping to win its first approval for the therapy, RVT-802, aimed at treating congenital athymia, a disorder affecting babies born without...
      UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial

      UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial

      Medical Dialogues Bureau8 Dec 2019 8:59 AM IST
      UCB's drug, Bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an...
      Dr Reddys launches generic version of Hemabate injection indicated for abortion in US

      Dr Reddys launches generic version of Hemabate injection indicated for abortion in US

      Medical Dialogues Bureau7 Dec 2019 12:46 PM IST
      Carboprost Tromethamine injection for aborting a pregnancy is a generic version of Pfizer's Hemabate injection in the strength of 250 mcg/mL, Dr...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok